Abbott Laboratories Corporation

Abbvie Inc.

John F Bauer

Azita Saleki-Gerhardt

Sanjay R Chemburkar

Ketan M Patel

Bikshandarkoil A Narayanan

Harry O Spiwek

Philip E Bauer

Kimberly A Allen

James A Morley

Glenn A Meyer

Stephen G Spanton

Rodger E Henry

Ramesh F Patel

Douglas M Shada

Ketan Patel

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Polymorph of a pharmaceutical

The present invention provides a non-solvated crystalline polymorph of terazosin monohydrochloride designated Form III and methods for its preparation. Also disclosed is terazosin monohydrochloride methanolate and processes for its production as well as processes for its conversion to other crystalline forms of terazosin monohydrochloride.

Terazosin monohydrochloride and processes and intermediate for its

A process for preparing a novel anhydrous crystalline polymorph of anhydrous 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl) piperazine monohydrochloride comprises contacting the known amorphous, crystalline dihydrate, or crystalline anhydrous form I of the compound with a polar organic solvent.

Terazosin polymorph and pharmaceutical composition

A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed, together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.

Acid salts of valproic acid having the structure: ##STR1## wherein M is potassium, cesium or rubidium. The salts of the invention are useful in the treatment of epileptic seizures, and can be conveniently formulated into oral dosage forms.

Acid salts of valproic acid

Growing community of inventors

Lake Bluff, IL, United States of America

John F Bauer